NURS 6521 Week 4 Assignment - Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders

Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders From the symptoms that the patient is presenting, it is possible that he has one of the gastrointestinal disorders, most likely the Irritable Bowel Syndrome (IBS). The most common signs for these disorders including abdominal pain, bloating/excess gas, constipation, diarrhea, vomiting, nausea, and heart burn (Yaccob & Mari, 2019). Hepatitis C can be ruled out because it presents somewhat different symptoms including bleeding, poor appetite, yellow eyes, itchy skin, and dark-colored urine. Appropriate drug therapy plan The severity of the symptoms will be assessed given the drugs he is taking at the moment. If mild, then giving the patient Rifaximin (Xifaxan) can help reduce diarrhea and bacterial overgrowth. The most important advice is to change lifestyle. Justification The other drugs have side effects that might worsen the diarrhea (Tuppin, Riviere & Sabate, 2019). However, the patient should change lifestyle, for instance, avoid drugs and drink 3 This case involves a patient (HL) presenting they symptoms of nausea, vomiting, and diarrhea. HL has a history of drug abuse as well as a possible Hepatitis C and is taking certain prescription drugs on a daily basis. From the symptoms that the patient is presenting, it is possible that he has one of the gastrointestinal disorders, most likely the Irritable Bowel Syndrome (IBS). Rifaximin (Xifaxan) can help reduce diarrhea and bacterial overgrowth. plenty of fluids. The patient should also exercise and get enough sleep while avoiding high-gas foods and take fiber supplements. Summary 4 References Tuppin, P., Riviere, S., & Sabate, J-M. (2019). Burden of drug use for gastrointestinal symptoms and functional gastrointestinal disorders in France. Therapeutic Advances in Gastroenterology. Weiskirchen, R., & Izzo, A. A. (2021). Insights in gastrointestinal and hepatic pharmacology. Frontiers in Pharmacology. Yaccob, A., Mari, A. (2019). Practical clinical approach to the evaluation of hepatobiliary disorders in inflammatory bowel disease. Frontline Gastroenterology, 10(3), 309-315.